Scholarly Index
Mark H. Rozenbaum
Pfizer (Netherlands); 2,454 total citations; 110 total publications; best world rank #124
Pfizer (Netherlands)
2,454Total citations
110Total publications
30H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Amyloidosis: Diagnosis, Treatment, Outcomes | Lifetime | 886 | NL 21 | 91.98 |
| Respiratory viral infections research | 2021-2025 | 349 | NL 14 | 94.34 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | 2021-2025 | 124 | NL 2 | 95.36 |
| Pneumonia and Respiratory Infections | 2021-2025 | 324 | NL 13 | 93.74 |
| Parathyroid Disorders and Treatments | 2021-2025 | 225 | NL 9 | 92.55 |
| Pneumocystis jirovecii pneumonia detection and treatment | 2021-2025 | 388 | NL 8 | 87.08 |
| Eosinophilic Disorders and Syndromes | 2021-2025 | 427 | NL 3 | 85.01 |